Knoglina Nasal Spray contains Calcitonin (Salmon) 200 IU as its active ingredient, a synthetic peptide hormone used primarily in the management of osteoporosis and Paget's disease of bone. Calcitonin acts by inhibiting osteoclastic bone resorption, thereby reducing bone turnover and increasing bone mineral density. This nasal formulation offers a non-invasive route of administration, enhancing patient compliance compared to injectable forms. Knoglina Nasal Spray is indicated for the treatment of postmenopausal osteoporosis in women who are at least five years postmenopause and for the relief of bone pain associated with Paget's disease. The spray is administered intranasally, typically once daily, with dosage adjustments based on clinical response and tolerability. Common adverse effects include nasal irritation, rhinitis, and occasional epistaxis. Patients with hypersensitivity to salmon calcitonin or any component of the formulation should avoid use. Caution is advised in individuals with a history of hypersensitivity reactions or asthma. Knoglina Nasal Spray should be used as part of a comprehensive treatment plan including adequate calcium and vitamin D supplementation. Regular monitoring of bone density and clinical status is recommended to assess therapeutic efficacy and guide ongoing treatment decisions.